BioLineRx (BLRX) vs Processa Pharmaceuticals (PCSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioLineRx is the larger company by market cap ($4.8 million vs $4.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLRX | PCSA |
|---|---|---|
| Share price | $0.9639 | $1.56 |
| Market cap | $4.80M | $4.37M |
| 1-day change | -8.20% | -7.69% |
| YTD return | -65.20% | — |
| 1-year return | -70.34% | — |
| 5-year return | -99.07% | — |
| EPS (TTM) | $0.00 | $-68.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.18M | — |
| Revenue growth (YoY) | -95.92% | — |
| Net income (latest FY) | $-2.03M | $-13.56M |
| Gross margin | 80.51% | — |
| Operating margin | -871.78% | — |
| Net margin | -171.69% | — |
| 52-week high | $3.95 | $8.88 |
| 52-week low | $0.78 | $1.04 |
| Distance from 52-week high | -75.60% | -82.43% |
| Analyst consensus | none | — |
| Avg. price target upside | +2182.39% | — |
| Average volume | 23.43K | 79.50K |
| Shares outstanding | 4.98M | 2.80M |
| Employees | 20 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Processa Pharmaceuticals
PCSA stock →Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
BLRX vs PCSA FAQ
Which is bigger, BioLineRx or Processa Pharmaceuticals?
BioLineRx (BLRX) is larger, with a market capitalization of $4.80M compared with $4.37M for Processa Pharmaceuticals (PCSA).
Are BioLineRx and Processa Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.